Complix Raises Additional €2M from Crédit Agricole Private Equity
Complix, a Hasselt, Belgium-based biopharmaceutical company that focuses on the discovery and development of Alphabodies™, a proprietary class of protein drugs, has raised an additional €2m from Crédit Agricole Private Equity as part of an extension of its Series A equity financing.
The financing will allow the company to build a preclinical portfolio of Alphabody™ based products for treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis, and for infectious diseases, in particular viral diseases such as influenza, HIV and RSV, and to develop its lead product up to regulatory filing for initiation of clinical trials in the second half of 2012.
In conjunction with the financing, Emmanuelle Coutanceau, PhD, from Crédit Agricole Private Equity, has joined Complix’ board of directors.
Founded two years ago and led by CEO Dr Mark Vaeck, the company is headquartered in in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg, where it established a fully owned subsidiary.